Innate Pharma SA
Nicolas MAROC, PhD, currently serves as the R&D Translational Molecular Biology Head at Innate Pharma since January 2017, bringing extensive experience in molecular diagnostics and product development. Prior roles include freelance consulting in diagnostics and biotechnology, and Associate Director of R&D at QIAGEN, where expertise encompassed molecular diagnosis assay design, Next Generation Sequencing (NGS) technology applications, and team management. Nicolas MAROC also held positions as R&D Manager and R&D Product Development Manager in earlier companies focusing on personalized health care. With a strong academic foundation in Immunology from Aix-Marseille University, Nicolas MAROC has contributed to viral vector development for gene therapy, molecular cytogenesis diagnosis, and has represented organizations in international congresses.
This person is not in any teams
This person is not in any offices
Innate Pharma SA
2 followers
Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.